Blog
RSS FeedPosted by Michael Wonder on 31 May 2021
State slower to ‘adopt new drugs’ than most of western Europe
31 May 2021 - Medicines regularly not worth approving at asking price. ...
Posted by Michael Wonder on 27 May 2021
Ireland an outlier without access to new cell and gene therapy, report says
27 May 2021 - Upfront costs high but treatments may cut long-term expense and boost patient results. ...
Posted by Michael Wonder on 17 Aug 2020
Irish pharmacists lobby for biosimilar substitution
17 August 2020 - Pharmacists in Ireland say the country is losing out on hundreds of millions of dollars in savings ...
Posted by Michael Wonder on 14 Jun 2020
Sacubitril/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system
12 June 2020 - The aim of this study was to evaluate the utilisation of Entresto in Ireland and compare patient ...
Posted by Michael Wonder on 16 Dec 2019
Vertex and Republic of Ireland expand long-term cystic fibrosis medicines reimbursement agreement to include triple combination therapy for all eligible patients ages 12 and over once licensed
13 December 2019 - Vertex Pharmaceuticals today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the ...
Posted by Michael Wonder on 06 Mar 2019
In UK and Ireland, SMA patients demand reimbursement for Spinraza
6 March 2019 - A drug appraisal committee of Britain’s NICE met in Manchester, England, for the third and final ...
Posted by Michael Wonder on 16 Jan 2019
Dublin warns medicine supply threatened by no-deal Brexit
16 January 2019 - More than half of Ireland’s medicines come from or are transited via the UK. ...
Posted by Michael Wonder on 23 Oct 2017
Dublin ramps up bid to lure post-Brexit European Medical Agency
23 October 2017 - Ireland’s industrial development agency joins campaign to place EMA alongside republic’s burgeoning pharmaceutical and biomedical sectors. ...